N

North Texas Clinical Trials | Fort Worth, TX

Research site
(Unclaimed)
Location
1650 W Rosedale, Suite 300, Fort Worth, Texas, United States of America
Site insights

Top conditions

Depression (11 trials)

Depressive Disorder (10 trials)

Major Depressive Disorder (8 trials)

Treatment-Resistant Depressive Disorder (2 trials)

Cognitive Dysfunction (2 trials)

Top treatments

Rapastinel
Iclepertin
Seltorexant
Troriluzole
Aticaprant
Ecopipam
Psilocybin
Liafensine
Quetiapine XR
BRII-296

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

11 of 22
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Enrolling
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Drug: Aticaprant
Other: Placebo

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling
Depressive Disorder, Major
Drug: Aticaprant

The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar diso...

Enrolling
Bipolar Disorder
Drug: JNJ-55308942
Drug: Placebo

The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depr...

Active, not recruiting
Depressive Disorder, Major
Drug: Placebo
Drug: Seltorexant

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Placebo
Drug: Iclepertin

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study.Participants who complete...

Invitation-only
Alzheimer Disease
AD
Device: Sensory Stimulation System (GS120) - Active

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

Trial sponsors

Allergan logo

Allergan (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems